A Phase 2 interventional study of VX-659 and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 47 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-22.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 18th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 15th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 3 started in 2017.
This study's enrollment of 124 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 41st largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 21 in phase 2, and was the 66th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double-blind, placebo- and tezacaftor/ivacaftor (TEZ/IVA)-controlled, parallel-group, 3-part, multicenter study designed to evaluate the safety and efficacy of VX-659 in triple combination (TC) with TEZ and IVA in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or TEZ/IVA (F/MF genotypes).
Key Inclusion Criteria:
Subjects must have an eligibleCFTR genotype.
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
Drug: Placebo (matched to VX-659/TEZ/IVA)
Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Drug: VX-659 · Drug: TEZ/IVA · Drug: IVA
Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Drug: VX-659 · Drug: TEZ/IVA · Drug: IVA
Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Drug: VX-659 · Drug: TEZ/IVA · Drug: IVA
Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
Drug: TEZ/IVA · Drug: IVA
Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
Drug: VX-659 · Drug: TEZ/IVA · Drug: IVA
Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
Drug: Placebo (matched to VX-659/TEZ/VX-561)
Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
Drug: VX-659 · Drug: TEZ · Drug: VX-561
Tablet for oral administration.
Drug pages: Tezacaftor · Ivacaftor
TEZ/IVA fixed-dose combination tablet for oral administration.
Also known as: VX-661/VX-770, Tezacaftor/Ivacaftor
Tablet for oral administration.
Also known as: VX-770, Ivacaftor
Placebo matched to VX-659 and TEZ/IVA.
Tablet for oral administration.
Also known as: VX-661, Tezacaftor
Tablet for oral administration.
Also known as: CTP-656
Placebo matched to VX-659, TEZ and VX-561.
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 Through Safety Follow-up (up to Day 61 for Part 1, Day 85 for Part 2 and Day 57 for Part 3)
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Day 29
Absolute Change in Sweat Chloride Concentrations
Sweat samples were collected using an approved collection device.
Time frame: From Baseline Through Day 29
Relative Change in ppFEV1
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline Through Day 29
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From Baseline at Day 29
Observed Pre-dose Concentration (Ctrough) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561
Time frame: Pre-dose at Day 15 and Day 29
Total of 124 participants were enrolled in this study (63 in Part 1, 36 in Part 2 and 25 in Part C). Out of 36 participants enrolled in Part 2, 7 participants discontinued treatment in run-in period and were not randomized in triple combination (TC) treatment period. Therefore, below results are presented for 117 participants.
| Milestone | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 11 | 20 | 22 | 11 | 18 | 6 | 19 |
| Completed | 10 | 11 | 20 | 22 | 11 | 18 | 6 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Participants with TEAEs | 9 | 10 | 15 | 17 | 9 | 15 | 6 | 18 |
| Participants with SAEs | 3 | 1 | 4 | 1 | 2 | 1 | 3 | 2 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 0.4 (-5.3 to 6.1) | 10.2 (4.8 to 15.5) | 12.0 (8.0 to 16.0) | 13.3 (9.5 to 17.1) | 0.0 (-3.9 to 3.9) | 9.7 (6.6 to 12.7) | -5.0 (-12.2 to 2.1) | 12.2 (8.3 to 16.2) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Absolute Change in Sweat Chloride Concentrations | 2.9 (-6.3 to 12.2) | -45.7 (-54.4 to -37.0) | -43.8 (-50.7 to -37.0) | -51.4 (-57.8 to -44.9) | 3.0 (-2.8 to 8.9) | -42.2 (-46.8 to -37.7) | -1.3 (-12.4 to 9.8) | -38.1 (-44.4 to -31.8) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Relative Change in ppFEV1 | 0.0 (-10.5 to 10.4) | 18.8 (8.9 to 28.7) | 21.1 (13.8 to 28.5) | 24.6 (17.6 to 31.6) | 0.1 (-7.1 to 7.3) | 17.3 (11.7 to 23.0) | -11.3 (-23.7 to 1.1) | 21.5 (14.6 to 28.4) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score | 4.7 (-7.5 to 16.8) | 24.6 (13.0 to 36.2) | 19.8 (11.0 to 28.6) | 21.8 (13.6 to 30.0) | 2.9 (-5.2 to 11.1) | 19.5 (13.1 to 25.9) | -4.1 (-17.8 to 9.6) | 14.7 (7.1 to 22.4) |
| nanogram per milliliter (ng/mL) | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|
| VX-659: Day 15 | 393 ± 604 | 622 ± 429 | 1100 ± 731 | — | 835 ± 474 | 1140 ± 646 |
| VX-659: Day 29 | 566 ± 861 | 699 ± 489 | 1080 ± 582 | — | 1070 ± 914 | 923 ± 582 |
| TEZ: Day 15 | 1910 ± 1360 | 1250 ± 907 | 1110 ± 455 | 1050 ± 473 | 1350 ± 1440 | 1000 ± 305 |
| TEZ: Day 29 | 1910 ± 1230 | 1050 ± 553 | 1010 ± 479 | 1150 ± 480 | 955 ± 422 | 776 ± 321 |
| M1-TEZ: Day 15 | 4390 ± 949 | 3710 ± 1230 | 4280 ± 1190 | 4160 ± 1260 | 4010 ± 1210 | 4060 ± 660 |
| M1-TEZ: Day 29 | 4300 ± 774 | 3650 ± 1280 | 3870 ± 1020 | 3790 ± 1080 | 3810 ± 1120 | 3660 ± 1190 |
| IVA: Day 15 | 824 ± 781 | 522 ± 567 | 423 ± 261 | 458 ± 239 | 313 ± 158 | — |
| IVA: Day 29 | 719 ± 604 | 443 ± 398 | 371 ± 220 | 490 ± 179 | 296 ± 175 | — |
| M1-IVA: Day 15 | 1200 ± 711 | 1050 ± 852 | 1170 ± 674 | 1310 ± 684 | 844 ± 622 | — |
| M1-IVA Day 29 | 1130 ± 682 | 1140 ± 950 | 1030 ± 460 | 1240 ± 321 | 866 ± 691 | — |
| VX-561: Day 15 | — | — | — | — | — | 380 ± 240 |
| VX-561: Day 29 | — | — | — | — | — | 288 ± 165 |
Collected over Day 1 Through Safety Follow-up (up to Day 61 for Part 1, Day 85 for Part 2 and Day 57 for Part 3). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/10 (0%) | 3/10 (30%) | 8/10 (80%) |
| Part 1: VX-659/TEZ/IVA TC - Low Dose | 0/11 (0%) | 1/11 (9.1%) | 10/11 (90.9%) |
| Part 1: VX-659/TEZ/IVA TC - Medium Dose | 0/20 (0%) | 4/20 (20%) | 15/20 (75%) |
| Part 1: VX-659/TEZ/IVA TC - High Dose | 0/22 (0%) | 1/22 (4.5%) | 17/22 (77.3%) |
| Part 2: TEZ/IVA | 0/11 (0%) | 2/11 (18.2%) | 8/11 (72.7%) |
| Part 2: VX-659/TEZ/IVA TC | 0/18 (0%) | 1/18 (5.6%) | 15/18 (83.3%) |
| Part 3: Placebo | 0/6 (0%) | 3/6 (50%) | 5/6 (83.3%) |
| Part 3: VX-659/TEZ/VX-561 TC | 0/19 (0%) | 2/19 (10.5%) | 18/19 (94.7%) |
| Event | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/10 | 1/11 | 2/20 | 1/22 | 2/11 | 1/18 | 3/6 | 1/19 |
| Pulmonary function test decreasedInvestigations | 1/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 0/6 | 0/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 0/6 | 1/19 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 0/6 | 1/19 |
| PyrexiaGeneral disorders | 0/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 0/6 | 1/19 |
| PneumoniaInfections and infestations | 0/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 0/6 | 1/19 |
| InfluenzaInfections and infestations | 0/10 | 0/11 | 1/20 | 0/22 | 0/11 | 0/18 | 0/6 | 0/19 |
| Respiratory tract infection viralInfections and infestations | 0/10 | 0/11 | 1/20 | 0/22 | 0/11 | 0/18 | 0/6 | 0/19 |
| Event | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC |
|---|---|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 | 3/11 | 6/20 | 4/22 | 2/11 | 4/18 | 2/6 | 4/19 |
| RalesRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 0/20 | 0/22 | 0/11 | 0/18 | 2/6 | 0/19 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 1/20 | 0/22 | 0/11 | 4/18 | 0/6 | 0/19 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/10 | 2/11 | 1/20 | 3/22 | 1/11 | 4/18 | 0/6 | 2/19 |
| HeadacheNervous system disorders | 0/10 | 1/11 | 4/20 | 4/22 | 0/11 | 3/18 | 1/6 | 1/19 |
| FatigueGeneral disorders | 0/10 | 2/11 | 2/20 | 0/22 | 1/11 | 0/18 | 1/6 | 0/19 |
| Blood creatine phosphokinase increasedInvestigations | 0/10 | 1/11 | 1/20 | 3/22 | 2/11 | 1/18 | 0/6 | 0/19 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/10 | 2/11 | 1/20 | 3/22 | 1/11 | 3/18 | 0/6 | 1/19 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 3/20 | 4/22 | 0/11 | 2/18 | 0/6 | 2/19 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/10 | 2/11 | 1/20 | 0/22 | 1/11 | 1/18 | 1/6 | 0/19 |
| Age, Customized(Participants) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=18 and <65 years | 10 | 11 | 20 | 22 | 11 | 18 | 6 | 19 | 117 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 7 | 7 | 12 | 4 | 6 | 3 | 11 | 54 |
| Male | 6 | 4 | 13 | 10 | 7 | 12 | 3 | 8 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 6 |
| Not Hispanic or Latino | 10 | 11 | 18 | 22 | 10 | 17 | 5 | 18 | 111 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| White | 10 | 11 | 20 | 22 | 11 | 16 | 6 | 17 | 113 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Participants) | Part 1: Placebo | Part 1: VX-659/TEZ/IVA TC - Low Dose | Part 1: VX-659/TEZ/IVA TC - Medium Dose | Part 1: VX-659/TEZ/IVA TC - High Dose | Part 2: TEZ/IVA | Part 2: VX-659/TEZ/IVA TC | Part 3: Placebo | Part 3: VX-659/TEZ/VX-561 TC | Total |
|---|---|---|---|---|---|---|---|---|---|
| <40 percent | 2 | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 8 |
| ≥40 to <70 percent | 6 | 9 | 13 | 13 | 8 | 12 | 5 | 13 | 79 |
| ≥70 to ≤90 percent | 2 | 2 | 6 | 7 | 3 | 5 | 1 | 4 | 30 |
| >90 percent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Feb 2018, 6 months.
Results were first posted in Apr 2021, 3 years 1 month after primary completion. A results delay was requested in Feb 2019.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 6 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →